MARC details
000 -LEADER |
fixed length control field |
03731nam a22005777a 4500 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
220124s20212021 xxu||||| |||| 00| 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
International Standard Serial Number |
0269-2813 |
024 ## - OTHER STANDARD IDENTIFIER |
Standard number or code |
10.1111/apt.16659 [doi] |
040 ## - CATALOGING SOURCE |
Original cataloging agency |
Ovid MEDLINE(R) |
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
PMID |
34850415 |
245 ## - TITLE STATEMENT |
Title |
Systematic review with meta-analysis: the impact of functional cure on clinical outcomes in patients with chronic hepatitis B. |
251 ## - Source |
Source |
Alimentary Pharmacology & Therapeutics. 55(1):8-25, 2022 01. |
252 ## - Abbreviated Source |
Abbreviated source |
Aliment Pharmacol Ther. 55(1):8-25, 2022 01. |
252 ## - Abbreviated Source |
Former abbreviated source |
Aliment Pharmacol Ther. 55(1):8-25, 2022 01. |
252 ## - Abbreviated Source |
Former abbreviated source |
Aliment Pharmacol Ther. 55(1):8-25, 2022 Jan. |
253 ## - Journal Name |
Journal name |
Alimentary pharmacology & therapeutics |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Year |
2022 |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Manufacturer |
FY2022 |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Publication date |
2022 Jan |
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
Publication status |
ppublish |
266 ## - Date added to catalog |
Date added to catalog |
2022-01-25 |
268 ## - Previous citation |
-- |
Alimentary Pharmacology & Therapeutics. 55(1):8-25, 2022 01. |
268 ## - Previous citation |
-- |
Alimentary Pharmacology & Therapeutics. 55(1):8-25, 2022 Jan. |
269 ## - Original dates |
Original fiscal year |
FY2022 |
520 ## - SUMMARY, ETC. |
Abstract |
AIM: To assess the impact of HBsAg loss on clinical outcomes following spontaneous and treatment-related HBsAg loss. |
520 ## - SUMMARY, ETC. |
Abstract |
BACKGROUND: Although hepatitis B surface antigen (HBsAg) loss is considered the ideal therapeutic endpoint for the treatment of chronic hepatitis B virus (HBV) infection, its impact on clinical outcomes remains uncertain. |
520 ## - SUMMARY, ETC. |
Abstract |
CONCLUSION: HBsAg loss is associated with a reduced risk of clinical outcomes. However, several shortcomings in the published studies prevent a more definitive conclusion on the potential benefits of HBsAg loss. Copyright (c) 2021 John Wiley & Sons Ltd. |
520 ## - SUMMARY, ETC. |
Abstract |
METHODS: We searched PUBMED, Embase, the Cochrane library, and published abstracts through to May 2021 for studies that reported HBsAg loss, had >1 year of follow-up and reported at least one clinical outcome in adults with chronic HBV infection. |
520 ## - SUMMARY, ETC. |
Abstract |
RESULTS: We identified 57 studies (258 744 HBsAg-positive patients, 63 270 with HBsAg loss). Based on 24 studies including 160 598 patients with and without HBsAg loss, HBsAg loss was associated with a non-significant 23% relative risk reduction of developing hepatocellular carcinoma (HCC) compared to those who remained HBsAg-positive (RR = 0.77; 95% CI: 0.38-1.57). In subgroup meta-analysis of 10 studies, treatment-related HBsAg loss was associated with a non-significant higher pooled proportion of HCC (0.94%) compared to spontaneous HBsAg loss (0.45%). HCC development after HBsAg loss was significantly higher in males, those with underlying cirrhosis, and those with a family history of HCC. HBsAg loss was associated with lower pooled proportions of incident cirrhosis, hepatic decompensation, overall and liver-related mortality compared to no HBsAg loss. Substantial heterogeneity was noted across studies for all outcomes. |
546 ## - LANGUAGE NOTE |
Language note |
English |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Carcinoma, Hepatocellular |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Hepatitis B |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Hepatitis B, Chronic |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
*Liver Neoplasms |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Adult |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Carcinoma, Hepatocellular/ep [Epidemiology] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Carcinoma, Hepatocellular/et [Etiology] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Hepatitis B Surface Antigens |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Hepatitis B virus |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Hepatitis B, Chronic/dt [Drug Therapy] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Humans |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Liver Neoplasms/ep [Epidemiology] |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Male |
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
Institution |
MedStar Washington Hospital Center |
656 ## - INDEX TERM--OCCUPATION |
Department |
Internal Medicine Residency |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Journal Article |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Sharma, Disha |
790 ## - Authors |
All authors |
Auh S, Ghany MG, Hu A, Majeed NA, Sharma D, Terry N, Vittal A |
856 ## - ELECTRONIC LOCATION AND ACCESS |
DOI |
<a href="https://dx.doi.org/10.1111/apt.16659">https://dx.doi.org/10.1111/apt.16659</a> |
Public note |
https://dx.doi.org/10.1111/apt.16659 |
942 ## - ADDED ENTRY ELEMENTS (KOHA) |
Koha item type |
Journal Article |
Item type description |
Article |